Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression.

Bardia A, et al. J Clin Oncol. 2024;42(15):1738-1744.

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.

Cortes J, et al. N Engl J Med. 2025;393(19):1912-1925.

Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.

Tolaney SM, et al. N Engl J Med. 2026;394(4):354-366.

Sacituzumab govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer.

Rugo HS, et al. J Clin Oncol. 2022;40(29):3365-3376.

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.

Dent R, et al. Ann Oncol. 2026:S0923-7534(26)00130-4.

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01.

Bardia A, et al. J Clin Oncol. 2025;43(3):285-296.

Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.

Modi S, et al. N Engl J Med. 2022;387(1):9-20.

Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer.

Bardia A, et al. N Engl J Med. 2024;391(22):2110-2122.

Implementing shared decision-making interventions in breast cancer clinical practice: a scoping review.

Oprea N, et al. BMC Med Inform Decis Mak. 2023;23(1):164.

Shared decision making in the care of patients with cancer

Shickh S, et al. Am Soc Clin Oncol Educ Book. 2023;43:e389516.

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations

D'Arienzo A, et al. EClinicalMedicine. 2023;62:102113.

Adverse events and impact on quality of life of antibody-drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta-analysis.

Perachino M, et al. Eur J Clin Invest. 2025;55(6):e70001.